Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
-- Attendees may request 1 x 1 meeting with management at meetings@hcwco.com --
--與會者可要求與管理層進行1 x 1次會議，地址為郵箱：Meetings@hcwco.com--
PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that Pasithea's management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference, to be held in New York City, September 11-13.
加利福尼亞州帕洛阿爾託和佛羅裡達州邁阿密，9月2023年07日(環球通訊社)--帕西婭治療公司納斯達克代碼：KTTA)(以下簡稱“帕西西亞”或“公司”)是一家專注於發現、研究和開發治療中樞神經系統疾病創新療法的生物技術公司。該公司今天宣佈，帕西西亞的管理團隊將參加9月11日至13日在紐約市舉行的H.C.溫賴特第25屆全球投資年會。
Attendees interested in 1 x 1 meetings are invited to request them through the conference's meeting scheduler at meetings@hcwco.com or by calling or emailing the company contact below.
對1 x 1會議感興趣的與會者可通過會議日程安排程式提出申請，網址為郵箱：Meetings@hcwco.com或致電或向下面的公司聯繫人發送電子郵件。
About Pasithea Therapeutics Corp.
Pasithea治療公司簡介
Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. With an experienced team of experts in the fields of neuroscience, translational medicine, and drug development, Pasithea is developing new molecular entities for the treatment of neurological disorders, including Neurofibromatosis type 1 (NF1), Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS).
Pasithea Treateutics是一家生物技術公司，主要致力於發現、研究和開發治療中樞神經系統(CNS)疾病和呼吸系統疾病的創新療法。憑藉在神經科學、轉化醫學和藥物開發領域經驗豐富的專家團隊，Pasithea正在開發用於治療神經系統疾病的新分子實體，包括1型神經纖維瘤病(NF1)、肌萎縮側索硬化症(ALS)和多發性硬化症(MS)。
Forward Looking Statements
前瞻性陳述
This press release contains statements that constitute "forward-looking statements." Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.
本新聞稿包含構成“前瞻性陳述”的陳述。前瞻性陳述受許多條件的制約，其中許多條件不在公司的控制範圍之內。雖然公司相信這些前瞻性陳述是合理的，但不應過度依賴任何此類前瞻性陳述，這些前瞻性陳述是基於公司在本新聞稿發佈之日所掌握的資訊。這些前瞻性陳述是基於當前的估計和假設，會受到各種風險和不確定因素的影響，包括但不限於該公司提交給美國證券交易委員會(美國證券交易委員會)的檔案中陳述的風險和不確定因素。因此，實際結果可能會有很大不同。除法律要求外，本公司不承擔在本新聞稿發佈之日後因新資訊、未來事件或其他原因而更新這些陳述的義務。
Company Contact
Patrick Gaynes
Corporate Communications
pgaynes@pasithea.com
+1 (310) 989-5666
公司聯繫人
帕特裡克·蓋恩斯
企業通信
郵箱：pgaynes@pasithea.com
+1(310)989-5666